Navigation Links
Next Generation Sequencing: Emerging Clinical Applications and Global Markets
Date:7/25/2013

rare genetic diseases and prenatal screening. The report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for clinical genetic testing.

 

REASONS FOR DOING THE STUDY

 

The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome. The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies). Beginning in 2005, the launch of next generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests. As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is still relatively young and emerging, yet it holds great commercial promise. Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future. At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential. These technical and market factors are driving this market so that in 2013, it
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. LIVE Twitter Chat Featuring Next-Generation Sequencing Expert from The Children’s Hospital of Philadelphia
2. Air Force support for a new generation of lithium-ion batteries
3. Tutela Launches Genesis II - Next Generation Wireless Medical Monitoring System
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
6. DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger
7. Impact with Martin Sheen Introducing Audiences to the Next Generation of Environmental Custodians
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. Clearbridge BioMedics Reveals ClearCell(R) FX, Next Generation Label-free Cancer Cell Enrichment System at ASCO 2013
10. The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments
11. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... REDWOOD CITY, Calif. , March 4, 2015 ... ACRX ), a specialty pharmaceutical company focused on ... the treatment of acute and breakthrough pain, today ... yearly 2014 financial results after market close on ... an investment-community conference call at 4:30 p.m. Eastern ...
(Date:3/4/2015)... -- Launched by the Assistance Publique ... December 2011, ,SARAH, - the French national collaborative ... in advanced hepatocellular carcinoma (HCC) has enrolled more than ... SARAH, a large French study of patients with advanced, ... completed patient enrolment, exceeding its 400-patient target, according to ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has announced ... - 2025" report to their offering. ... extensive study on the marketed and pipeline gene therapies. ... this field for over a decade but there are ... one approved in the EU). There are many promising ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... Jan. 12, 2012  Inverseon, Inc., a pharmaceutical company developing ... that while it anticipates that its asthma program will ... cessation as the initial indication for INV102. ... smoking cessation, and also an inhaled COPD program, makes ...
... ANNAPOLIS, Md., Jan. 11, 2012 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that Eric I. ... Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, ... Room/Room 2 at the Hard Rock Hotel, Hollywood Florida.  ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Inverseon Focuses on Mucous and Smoking Cessation 2PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
(Date:2/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... groundbreaking payment method. Payment accounts may be selected via ... accessed if both the speech (the word associated with ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... make a vaccine to protect against 2009 influenza A (H1N1) ... process for future flu seasons. The goal is to shorten ... manufacture the vaccines for them. In a paper ... & Selection , Rice researchers described a new method to ...
... PARK, PAOzone, the main component of air pollution, or ... oxygen reacts with other chemicals. Although ozone pollution is ... infiltrates indoor environments like homes and offices. Ozone can ... lights, and some electrostatic air purification systems, all of ...
... genes can reveal not only the "lifestyle" of marine microbes ... finding means researchers may be able to predict the types ... the genomes of just a few dominant species, according to ... Wales. As well, it may reveal new insights into the ...
Cached Biology News:Rice researchers seek better vaccine procedure 2Rice researchers seek better vaccine procedure 3Houseplants cut indoor ozone 2Genomes reveal bacterial lifestyles: Research 2
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
Biology Products: